Professional Experience Bruce C. Haas has been a partner at the firm since 1989 and focuses his practice on complex patent litigation. He has extensive courtroom experience and has served as lead trial counsel in patent infringement litigations involving pharmaceuticals and mechanical devices. Mr. Haas's practice has involved many diverse technologies including high strength fibers, aerospace materials, automotive parts, plastic container manufacturing, pharmaceuticals and electrochemical devices. Mr. Haas has served as trial counsel in patent litigations on behalf of Bristol-Myers Squibb, ElringKlinger AG, Merck, Husky Injection Molding Machines, UCB Pharma, AstraZeneca, Cytec, Eltech Systems, Upsher-Smith Laboratories, Searle and Pharmacia. In addition to litigation, Mr. Haas has wide experience in patent arbitration, patent evaluations and opinion work in fields as diverse as mechanical pumping devices to advanced composite materials. Mr. Haas has served as Managing Partner in both the New York and Washington, D.C. offices. He presently serves on the firm's Management Committee. He has recently been elected a Fellow of the Litigation Counsel of America. Awards and Recognition Listed in Legal Media Group Guide to the World's Leading Patent Law Practitioners 2007. He was also listed in Legal 500 2008 and 2009 for Patent litigation: full coverage. Professional Activities New York Intellectual Property Law Association (Board of Directors); American Bar Association; New York and District of Columbia Bar Associations; New Jersey Intellectual Property Law Associations; ITC Trial Lawyers Association; Intellectual Property Institute of Canada Representative Matters · UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to Keppra®, a leading epilepsy medicine. · ElringKlinger against Federal-Mogul on patents relating to automotive gaskets. · Pharmacia, G.D. Searle, and Monsanto against the University of Rochester on patents relating to the blockbuster product Celebrex®. · AstraZeneca against Teva on patents relating to Seroquel®, an antipsychotic medicine. · Bristol-Myers Squibb against BenVenue on patents relating to the cancer drug Taxol®. · Husky Injection Molding against Mold Masters on patents relating to injection molding machines. · Monsanto Co. & Johnson Controls, Inc. against Continental Can on plastic bottle technology. · Cytec on high composite laminate technology. · Upsher Smith Laboratories against Schering Plough on potassium products. · Eltech Systems against Engelhard and Electrocatalytic Inc. on electrocatalytic cell technology. · Dupont against Akzo on high strength fiber (Kevlar®) technology. Representative Cases Unigene Laboratories, Inc. and Upsher-Smith Laboratories, Inc v. Apotex, Inc.
United States Court of Appeals for the Federal Circuit AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd., v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd and Sandoz, Inc.
Fed. Cir. 2009 Unigene Labs., Inc., et al. v. Apotex, Inc., et al.
S.D.N.Y., 2009 AstraZeneca Pharmaceutical LP et al. v. Teva Pharmaceuticals USA, Inc, et al.
D.N.J. 2008 AstraZeneca Pharmaceuticals LP, et al. v. Teva Pharmaceuticals USA, Inc., et al. D.N.J. 2007 UCB Societe Anonyme & UCB Pharma Inc. v. Mylan Laboratories, Inc. et al.
N.D. GA 2006 Federal-Mogul Corp. and Felt Products Mfg. Co. v. ElringKlinger AG
D.N.J. 2004 University of Rochester v. G.D. Searle and Co., Inc., Pfizer Inc., Monsanto Co., and Pharmacia Corp.
Fed. Cir. 2004 University of Rochester v. G.D. Searle & Co., Inc., Pfizer Inc., Monsanto Co., and Pharmacia Corp.
W.D.N.Y. 2003 Publications Patent Policing
European Pharmaceutical Contractor
March 2010 Patent Enforcement: Licensing and Litigation Considerations
IP Value 2008
2008 Events Obviousness Under 35 U.S.C. §103 in the United States
IBC's Biotech and Pharmaceutical Patenting Conference
January 27, 2009 U.S. Claim Construction Since Phillips Intellectual Property Institute of Canada, 80th Annual Meeting
September 28, 2006 Interesting Developments in the Monsanto v. Schmeiser Decision: Patentable Subject Matter and Damages
Intellectual Property Institute of Canada, 78th Annual Meeting
October 14-16, 2004 Update: Written Description and Enablement Issues NYIPLA CLE Luncheon
April 25, 2003 Festo: To Be Measured By All That We Foresee
Intellectual Property Institute of Canada
Fall 2002 |